These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28052356)

  • 1. An Overview of the Changing Landscape of Treatment for Advanced Melanoma.
    Lee CS; Thomas CM; Ng KE
    Pharmacotherapy; 2017 Mar; 37(3):319-333. PubMed ID: 28052356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Therapeutic Landscape of Advanced Melanoma.
    Henriques V; Martins T; Link W; Ferreira BI
    Curr Pharm Des; 2018; 24(5):549-558. PubMed ID: 29366407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in malignant melanoma.
    Atkinson V
    Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Melanoma update].
    Longvert C; Saiag P
    Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma.
    Franke V; van der Hiel B; van de Wiel BA; Klop WMC; Ter Meulen S; van Akkooi ACJ
    Eur J Cancer; 2018 Feb; 90():149-152. PubMed ID: 29224902
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
    Rothermel LD; Zager JS
    Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Melanoma.
    Glitza Oliva IC; Alqusairi R
    Adv Exp Med Biol; 2018; 995():43-63. PubMed ID: 30539505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy for malignant melanoma].
    Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
    Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major Changes in Systemic Therapy for Advanced Melanoma.
    Thompson JA
    J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):638-40. PubMed ID: 27226502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
    Burke EE; Zager JS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous melanoma.
    Eggermont AM; Spatz A; Robert C
    Lancet; 2014 Mar; 383(9919):816-27. PubMed ID: 24054424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
    Levine O; Devji T; Xie F
    Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
    [No Abstract]   [Full Text] [Related]  

  • 16. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
    Lau PK; Ascierto PA; McArthur G
    Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma: from darkness to promise.
    Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
    Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current trends in the treatment of malignant melanoma.
    Valko-Rokytovska M; Bruchata K; Simkova J; Milkovicova M; Kostecka Z
    Neoplasma; 2016; 63(3):333-41. PubMed ID: 26925781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
    Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
    Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.